SensoLyte® 520 MMP-13 Assay Kit Fluorimetric - 1 kit
- Cat.Number : AS-71156
- Manufacturer Ref. :
-
Availability :
In stock
- Shipping conditions : Ice fees will apply
Alternative choices
Matrix metalloproteinases (MMPs) belong to a family of secreted or membrane-associated proteins capable of digesting extracellular matrix components. MMP-13 (collagenase-3, rat collagenase) is involved in quite a few diseases such as arthritis and asthma.
SensoLyte® 520 MMP-13 Assay Kit uses a 5-FAM (fluorophore) and QXL™ 520 (quencher) labeled FRET peptide substrates for continuous measurement of the enzyme activities. In an intact FRET peptide, the fluorescence of 5-FAM is quenched by QXL™ 520. Upon the cleavage of the FRET peptide by MMP-13, the fluorescence of 5-FAM is recovered, and can be continuously monitored at excitation/emission = 490 nm/520 nm. With superior fluorescence quantum yield and longer emission wavelength, 5-FAM/QXL™ 520 based FRET peptide is less interfered by the autofluorescence of test compounds and cellular components and provides better assay sensitivity.
Members of the MMP family have poor substrate sequence specificity, making it difficult to use a peptide substrate alone to differentiate the activity of a particular MMP from other MMPs. If several MMPs are coexisting in your samples and you would like to specifically measure MMP-13 activity, please choose the SensoLyte® Plus MMP-13 Assay Kit, Cat# AS-72019.
Specifications
Packaging | |
Kits components |
|
---|---|
Chemistry | |
UniProt number |
|
Properties | |
Absorbance (nm) |
|
Emission (nm) |
|
Storage & stability | |
Storage Conditions |
|
Activity | |
Application | |
Biomarker Target | |
Detection Method | |
Detection Limit |
|
Research Area | |
Sub-category Research Area | |
Usage |
|
Downloads
You may also be interested in the following product(s)
Citations
MMP13 is a critical target gene during the progression of osteoarthritis
Arthritis Res Ther. . 2013 Jan 08 ; 15(1) R5 | DOI : 10.1186/ar4133
- M. Wang
β-Adrenergic receptor stimulation transactivates protease-activated receptor 1 via matrix metalloproteinase 13 in cardiac cells
Circulation . 2012 May 18 ; 125(24) 2993 | DOI : 10.1161/CIRCULATIONAHA.111.066787
- F. Jaffré
Urine matrix metalloproteinases (MMPs) as biomarkers for the progression of fracture healing.
Injury . 2012 Mar 01 ; 43(3) 274 | DOI : 10.1016/j.injury.2011.05.038
- N.A. Wigner
Matrix metalloproteinase 12-deficiency augments extracellular matrix degrading metalloproteinases and attenuates IL-13-dependent fibrosis
J Immunol . 2010 Apr 01 ; 184(7) 3955 | DOI : 10.4049/jimmunol.0903008
- S.K. Madala
Doxycycline-mediated inhibition of matrix metalloproteinases improves healing after rotator cuff repair
Am J Sports Med . 2009 Oct 13 ; 38(2) 308 | DOI : 10.1177/0363546509347366
- A. Bedi
Matrix metalloproteinase inhibitors prevent a decrease in the mechanical properties of stress-deprived tendons: an in vitro experimental study
Am J Sports Med . 2007 Feb 09 ; 35(5) 763 | DOI : 10.1177/0363546506296043
- S.P. Arnoczky
Avenanthramide C as a novel candidate to alleviate osteoarthritic pathogenesis.
BMB Rep. . 2021 Oct 03 ; 54(10) 528 | DOI : 10.5483/BMBRep.2021.54.10.108
- TT. Tran
- et al
MIA/CD-RAP Regulates MMP13 and Is a Potential New Disease-Modifying Target for Osteoarthritis Therapy
Cells . 2023 Jan 05 ; 12(2) 229 | DOI : https://doi.org/10.3390/cells12020229
- S. Staebler
- et al
SK-216, a Novel Inhibitor of Plasminogen Activator Inhibitor-1, Suppresses Lung Metastasis of Human Osteosarcoma
Int. J. Mol. Sci. . 2018 Nov 01 ; 19(3) 736 | DOI : https://doi.org/10.3390/ijms19030736
- M. Tsuge
- et al
Functional characterization of selective exosite binding inhibitors of matrix metalloproteinase-13 (MMP-13) – experimental validation in human breast and colon cancer.
Biosci Biotechnol Biochem . 2016 Nov 01 ; 80(11) 2122 | DOI : https://www.tandfonline.com/loi/tbbb20
- R. Kothapalli
- et al